294 related articles for article (PubMed ID: 10639033)
21. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)--preliminary results of phase II clinical application.
Caudana R; Morana G; Pirovano GP; Nicoli N; Portuese A; Spinazzi A; Di Rito R; Pistolesi GF
Radiology; 1996 May; 199(2):513-20. PubMed ID: 8668804
[TBL] [Abstract][Full Text] [Related]
22. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine.
Grazioli L; Morana G; Federle MP; Brancatelli G; Testoni M; Kirchin MA; Menni K; Olivetti L; Nicoli N; Procacci C
Radiology; 2001 Dec; 221(3):731-9. PubMed ID: 11719669
[TBL] [Abstract][Full Text] [Related]
23. Gadobenate dimeglumine (Gd-DTPA) vs gadopentetate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio.
Pediconi F; Fraioli F; Catalano C; Napoli A; Danti M; Francone M; Venditti F; Nardis P; Passariello R
Radiol Med; 2003; 106(1-2):87-93. PubMed ID: 12951555
[TBL] [Abstract][Full Text] [Related]
24. Gadobenate dimeglumine (BOPTA) enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis.
Manfredi R; Maresca G; Baron RL; De Franco A; De Gaetano AM; Cotroneo AR; Pirovano G; Spinazzi A; Marano P
J Magn Reson Imaging; 1998; 8(4):862-7. PubMed ID: 9702888
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Gadolinium-BOPTA and Ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient.
Wersebe A; Wiskirchen J; Decker U; Schick F; Dietz K; Müller-Schimpfle M; Claussen CD; Pereira PL
Invest Radiol; 2006 Mar; 41(3):264-71. PubMed ID: 16481909
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation.
Pastor CM; Planchamp C; Pochon S; Lorusso V; Montet X; Mayer J; Terrier F; Vallee JP
Radiology; 2003 Oct; 229(1):119-25. PubMed ID: 12944603
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of gadobenate dimeglumine in hepatocellular carcinoma: results from phase II and phase III clinical trials in Japan.
Tanimoto A; Kuwatsuru R; Kadoya M; Ohtomo K; Hirohashi S; Murakami T; Hiramatsu K; Yoshikawa K; Katayama H
J Magn Reson Imaging; 1999 Sep; 10(3):450-60. PubMed ID: 10508308
[TBL] [Abstract][Full Text] [Related]
28. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
Balci NC; Inan N; Anik Y; Erturk MS; Ural D; Demirci A
Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
[TBL] [Abstract][Full Text] [Related]
29. Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine.
Stocker D; Hectors S; Bane O; Vietti-Violi N; Said D; Kennedy P; Cuevas J; Cunha GM; Sirlin CB; Fowler KJ; Lewis S; Taouli B
Eur Radiol; 2021 Dec; 31(12):9306-9315. PubMed ID: 34043055
[TBL] [Abstract][Full Text] [Related]
30. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
[TBL] [Abstract][Full Text] [Related]
31. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison.
Grazioli L; Morana G; Kirchin MA; Caccia P; Romanini L; Bondioni MP; Procacci C; Chiesa A
J Magn Reson Imaging; 2003 May; 17(5):593-602. PubMed ID: 12720270
[TBL] [Abstract][Full Text] [Related]
32. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children.
Colosimo C; Demaerel P; Tortori-Donati P; Christophe C; Van Buchem M; Högström B; Pirovano G; Shen N; Kirchin MA; Spinazzi A
Pediatr Radiol; 2005 May; 35(5):501-10. PubMed ID: 15678342
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy of gadobenate dimeglumine vs gadopentetate dimeglumine in contrast- enhanced magnetic resonance imaging for diagnosis of solitary brain metastases].
Wang QJ; Wang Y; Xu X; Xiao H; Ma L
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):1968-73. PubMed ID: 22200693
[TBL] [Abstract][Full Text] [Related]
34. Dose-Lowering in Contrast-Enhanced MRI of the Central Nervous System: A Retrospective, Parallel-Group Comparison Using Gadobenate Dimeglumine.
DeLano MC; Spampinato MV; Chang EY; Barr RG; Lichtenstein RJ; Colosimo C; Vymazal J; Wen Z; Lin DDM; Kirchin MA; Pirovano G
J Magn Reson Imaging; 2021 Nov; 54(5):1660-1675. PubMed ID: 34018290
[TBL] [Abstract][Full Text] [Related]
35. The relationship between liver function and liver parenchymal contrast enhancement on Gd-BOPTA-enhanced MR imaging in the hepatocyte phase.
Zhao X; Huang M; Zhu Q; Wang T; Liu Q
Magn Reson Imaging; 2015 Jul; 33(6):768-73. PubMed ID: 25842259
[TBL] [Abstract][Full Text] [Related]
36. Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators.
Essig M; Tartaro A; Tartaglione T; Pirovano G; Kirchin MA; Spinazzi A
Acad Radiol; 2006 Jun; 13(6):744-51. PubMed ID: 16679277
[TBL] [Abstract][Full Text] [Related]
37. Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis.
Yeom SK; Byun JH; Kim HJ; Park SH; Kim N; Shin YM; Kim PN
Magn Reson Imaging; 2013 Jul; 31(6):911-7. PubMed ID: 23598063
[TBL] [Abstract][Full Text] [Related]
38. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
[TBL] [Abstract][Full Text] [Related]
39. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
40. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
